Ispectamab debotansine is under clinical development by Bristol-Myers Squibb and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ispectamab debotansine’s likelihood of approval (LoA) and phase transition for Refractory Multiple Myeloma took place on 24 Mar 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 24 Mar 2021 increased Ispectamab debotansine’s LoA and PTSR for Relapsed Multiple Myeloma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ispectamab debotansine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ispectamab debotansine overview

CC-99712 is under development for the treatment of relapsed and refractory multiple myeloma. It is administered through intravenous route. The drug candidate acts by targeting B-cell maturation antigen (BCMA) and is developed based on cell-free biologics development platform Xpress CF technology.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Quick View Ispectamab debotansine LOA Data

Report Segments
  • Innovator
Drug Name
  • Ispectamab debotansine
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.